Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL-1: GVAX vs Docetaxel in mHRPC
NCT00089856Phase 3Terminated
- Sponsor
- Cell Genesys
- Start
- Jul 2004
- Primary completion
- Oct 2008
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of GVAX pancreatic cancer vaccine in prostate cancer (PCa) (2 arms), sponsored by Cell Genesys. Primary endpoint: Overall Survival. Started Jul 2004; status: terminated.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00089856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089856.